AmpliPhi Biosciences Corporation (NYSE American: APHB) announced on 5/7/2018 a poster presentation of a successful case study of a patient with cystic fibrosis, suffering from recurrent multi-drug resistant (MDR)  Pseudomonas aeruginosa  (P. aeruginosa) pneumonia, who received treatment with AB-PA01, AmpliPhi’s investigational bacteriophage drug candidate. The study will be presented at the 41st European Cystic Fibrosis Conference (EFCS), being held June 6-9, 2018 in Belgrade, Serbia.

The presentation describes the case of a 26-year old patient with cystic fibrosis (CF) listed for a double lung transplant, who developed multiple episodes of MDR  P. aeruginosa  pneumonia and had multiple CF exacerbations. Prior to treatment with AB-PA01, the patient received multiple courses of antibiotics, including colistin, but due to renal failure, colistin administration was discontinued.

The U.S. FDA granted an emergency IND to administer AmpliPhi’s AB-PA01 as an adjunctive treatment to systemic antibiotics. AB-PA01 was administered via intravenous route every six hours for eight weeks.

Treatment with AB-PA01 was well tolerated and the patient’s infection resolved. No recurrence of pneumonia or CF exacerbation was reported during the two-month follow-up period after the completion of treatment with AB-PA01. The patient’s renal failure resolved.

"The patient responded to the combination of AB-PA01 and antibiotic therapy based on an improvement in objective clinical criteria,” said Saima Aslam, M.D., Director, Solid Organ Transplant Infectious Diseases, University of California San Diego School of Medicine and the treating physician. “Furthermore, treatment with AB-PA01 was safe and well-tolerated. In this case study, bacteriophage therapy has demonstrated to hold much promise for patients with cystic fibrosis suffering from multidrug resistant pulmonary bacterial infections."


Bacteriophages have been used in a number of cases where patients have run out of antibiotic options to treat resistant bacterial infections. Due to the renewed interest in bacteriophage therapy we recently wrote a primer on bacteriophages which can be found here.http://www.cafepharma.com/cpwire/article/Phage-Based-Therapy---A-Primer/...